PEStore

Venture Capital

ARCH Venture

ARCH Venture backs early-stage and high-growth companies, typically pre-profit, from Chicago, Illinois, United States. It states a focus on healthcare & life sciences and software & internet.

Capital raised$6.7bnacross 9 SEC-filed vehicles
Most recent fund2023filing since 2013
HeadquartersChicago, Illinois, United States
Largest single fund$2.8bn

Stated investment criteria

What ARCH Venture says it buys

Read from ARCH Venture’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.

People listed on its team page191

A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. The team figure counts the people the firm shows on one team page, so it is a floor rather than a headcount: firms that split their team across tabs or load it in pages will read low. Nothing here is a commitment by ARCH Venture to consider any particular business, and nothing on this page is represented as being for sale.

SEC filings

What ARCH Venture has raised

From this firm's own Form D filings. A fund files one within fifteen days of its first sale, under penalty of perjury, which makes these the hardest numbers on the page.

Vehicles filed9
Total capital raised$6.7bn
Largest single vehicle$2.8bn
Filing history2013 to 2023
Smallest accepted commitment$250k
Filed fromILLINOIS

Form D covers US-domiciled vehicles raised from accredited investors. It will not capture a fund raised outside the United States, separately managed accounts, or capital deployed off balance sheet, so treat these as a floor rather than a total.

Regulatory record

How ARCH Venture is registered

From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.

Adviser statusExempt reporting adviser
Regulatory assets under managementNot reported by an ERA
Private funds advised13 · $11bn gross
SEC adviser numberCRD 158196

An exempt reporting adviser is not required to report regulatory assets under management, so the blank above means the question was not asked rather than that the answer is unknown. Where a figure exists it is the gross asset value of the private funds the firm advises, which is a different and usually larger measure.

Portfolio

Disclosed holdings

Companies ARCH Venture lists on its own website. 1 carry a stated investment year.

CompanyInvestedYears heldRecorded transaction
SonoThera20260
908 Devices
Accompany Health
Agios
Akamis Bio
Aledade
Alnylam
Altos Labs
Arbor Biotechnologies
Arraybiopharma
Arsenal Biosciences
Aspen Neuroscience
BE Biopharma
Basking Biosciences
Bit Bio
Bluebirdbio
Boundlessbio
Brii Biosciences
CStone Pharmaceuticals
Carricktherapeutics
Codiakbio
Corporate
Curie Bio
Cytrellis Biosystems
Decode
Denali Therapeutics
Dispatch Biotherapeutics
Elephas Biosciences
Encoded Therapeutics
Encodia
Erasca
Faraday Pharmaceuticals
GRAIL
Gate Bioscience
Generate Biomedicines
Gossamerbio
Grail (Acquired)
HiberCell
Homeward Health
Homologymedicines
Huamedicine
Illumina
Insitro
JUST Biotherapeutics (Acquired)
JW Therapeutics
Jaguar Gene Therapy
Juno Therapeutics (Acquired)
Kardigan
Kura Oncology
Kythera Biopharmaceuticals (Acquired)
Lifordi Immunotherapeutics
Lightcast Discovery
Lyellbiotech
Magnet Biomedicine
Mallinckrodt
Matter Neuroscience
Metsera (Acquired)
Moleculent AB
Moonwalk Biosciences
ONI
Omniome (Acquired)
OneBioMed
Parabilis Medicines
Paradigm Health
Perkinelmer
Pheast Therapeutics
Protillion Biosciences
Qihan Biotech
Quantum Circuits
RIPPL Care
Reactive Biosciences
Receptos
Recuro Health
Resilience
RhyGaze AG
Sana
Scale Biosciences
Scholarrock
SciNeuro Pharmaceuticals
Singleron Biotechnologies
Singular Genomics Systems
Skylark Bio
Slingshot Biosciences
SunBird Bio
Synchron
Syros
Tenvie
Transcenta Holding
Treeline Biosciences
Trotana Therapeutics
Twist Bioscience
Ultivue
Unitybiotechnology
Vir Biotechnology
Vividion
Vizgen
Xaira Therapeutics
eGenesis
hC Bioscience
nChroma Bio

Compiled from ARCH Venture’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.

Valuation context

Transaction values in Healthcare & Life Sciences

What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.

Median consideration$110m
Middle 50%$30m-$318m
Revenue multiple2.8×
EBITDA multiple12.5×

The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.

For owners

Own a healthcare & life sciences business?

The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.

Request a confidential valuation

For investors

Is this ARCH Venture?

Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.

Claim or correct this profile

Targeted buyer search

Which hundred of these would actually buy your business?

A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.

See how it works

Comparable investors

Similar mandates

Other venture capital investors active in healthcare & life sciences.